ARS Pharmaceuticals (SPRY) Accumulated Depreciation & Amortization (2021 - 2024)
ARS Pharmaceuticals (SPRY) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $100000.0 as the latest value for Q4 2024.
- Quarterly Accumulated Depreciation & Amortization changed 0.0% to $100000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Dec 2024, changed 0.0% year-over-year, with the annual reading at $100000.0 for FY2024, 0.0% changed from the prior year.
- Accumulated Depreciation & Amortization hit $100000.0 in Q4 2024 for ARS Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $132000.0 in Q1 2024 to a low of -$612000.0 in Q2 2024.
- Historically, Accumulated Depreciation & Amortization has averaged $19000.0 across 4 years, with a median of $100000.0 in 2022.
- Biggest five-year swings in Accumulated Depreciation & Amortization: soared 614.29% in 2022 and later tumbled 795.45% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $14000.0 in 2021, then skyrocketed by 614.29% to $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for SPRY at $100000.0 in Q4 2024, $100000.0 in Q3 2024, and -$612000.0 in Q2 2024.